2005. Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Neurosci Lett
384, 23–8., , , , and .
2000. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet
355, 1696–7., , , and .
N-acetyl-L-aspartic acid: A literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev
13, 23–31. and .
1999. Inflammatory CNS demyelination: Histopathologic correlation with in vivo quantitative proton MR spectroscopy. Am J Neuroradiol
20, 1619–27., , , et al.
1988. The neurobiology of N-acetylaspartylglutamate. Int Rev Neurobiol
30, 39–100. and .
1998. Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl
53, 127–40. and .
1993. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci
15, 289–98., and .
2000. Subcortical ischemic vascular dementia: Assessment with quantitative MR imaging and 1H MR spectroscopy. Am J Neuroradiol
21, 621–30., , , et al.
2001. (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport
12, 2315–7., , , et al.
2004. Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res
1003, 26–35., , , and .
2010. Evidence of neurodegeneration in brains of older adults who do not yet fulfill MCI criteria. Neurobiol Aging
31, 368–77., , , et al.
2005. Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients. Neurology
64, 282–9., , , et al.
2002. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain
125, 2332–41., , , and .
1997. The neurochemistry of Alzheimer's disease. Acta Neurol Belg
97, 67–84. and .
1997. Frontotemporal dementia and early Alzheimer disease: Differentiation with frontal lobe H-1 MR spectroscopy. Radiology
203, 829–36., , and .
2005. Proton magnetic resonance spectroscopy and magnetoencephalographic estimation of delta dipole density: A combination of techniques that may contribute to the diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord
20, 169–77., , , et al.
2005. Global prevalence of dementia: A Delphi consensus study. Lancet
366, 2112–7., , , et al.
2008. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging
29, 1456–65., , , et al.
1989. Differences in the metabolism of inositol and phosphoinositides by cultured cells of neuronal and glial origin. Biochim Biophys Acta
1004, 169–79., , , and .
2008. Memantine decreases hippocampal glutamate levels: A magnetic resonance spectroscopy study. Prog Neuropsychopharmacol Biol Psychiatry
32, 1005–12., , , , and .
1995. Quantitative in vivo 1H nuclear magnetic resonance spectroscopic imaging of neuronal loss in rat brain. Neuroscience
69, 1095–101., , , et al.
2001. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology
57, 930–2., , , et al.
2006. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl)
188, 509–20., , , and .
2008. A detailed analysis of localized J-difference GABA editing: theoretical and experimental study at 4 T. NMR Biomed
21, 22–32., , , and .
2000. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology 2000; 55: 210–7., , , , , , et al.
2008. Alzheimer disease: Postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology
248, 210–20., , , et al.
2002. 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. J Int Neuropsychol Soc
8, 934–42., , , et al.
2007. Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging
28, 1330–9., , , et al.
2007. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology
68, 1603–06., , , et al.
2006. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci USA
103, 702–07., , , et al.
2000. Membrane breakdown in acute and chronic neurodegeneration: Focus on choline-containing phospholipids. J Neural Transm
N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: A preliminary proton nuclear magnetic resonance study. Neurology
42, 1578–85., , , and .
N-acetyl-aspartyl-glutamate: Regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J Neurochem
43, 1136–42., and .
2003. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry
160, 2003–11., , , et al.
1999. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology
52, 691–9., , , et al.
2003. Reduced glutamate neurotransmission in patients with Alzheimer's disease – an in vivo (13)C magnetic resonance spectroscopy study. Magma
16, 29–42., , and .
2006. Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy. Neurobiol Aging
27, 926–32., , , et al.
1994. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging. Ann Neurol
36, 40–7., , , et al.
2006. Magnetic resonance spectroscopic study of Alzheimer's disease and frontotemporal dementia/Pick complex. Neuroreport
17, 413–6., , , and .
1994. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med
32, 110–5., , and .
1993. Clinical studies in Alzheimer patients with positron emission tomography. Behav Brain Res
1990. Decreased uptake and binding of 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J Neural Transm Park Dis Dement Sect
2, 215–24., , , et al.
1995. Kinetic analysis of regional (S)(–)11C-nicotine binding in normal and Alzheimer brains – In vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord
9, 21–7., , , and .
2008. Longitudinal metabolic and cognitive changes in mild cognitive impairment patients. Alzheimer Dis Assoc Disord
22, 269–77., , , et al.
2005. Current epidemiology of mild cognitive impairment and other predementia syndromes. Am J Geriatr Psychiatry
13, 633–44., , , et al.
1996. 1H-MRS, MRI-based hippocampal volumetry, and 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer's disease. J Am Geriatr Soc
44, 133–8., , , et al.
1997. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech Ageing Dev
97, 9–14., , , et al.
1999. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol
56, 303–08., , , , and .
1999. In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease. Arch Gen Psychiatry
56, 185–92., , , and .
2005. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab
25, 1528–47., , , et al.
1999. A 1H MRS study of probable Alzheimer's disease and normal aging: Implications for longitudinal monitoring of dementia progression. Magn Reson Imaging
17, 291–9., , , et al.
2003. Clinical experience with 13C MRS in vivo. NMR Biomed
16, 358–69., , , and .
1997. Changes of hippocampal N-acetylaspartate and volume in Alzheimer's disease: A proton MR spectroscopic imaging and MRI study. Neurology
49, 1513–21., , , et al.
2003. Different patterns of N-acetylaspartate loss in subcortical ischemic vascular dementia and AD. Neurology
61, 358–64., , , et al.
2002. Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology
58, 928–35., , , et al.
2001. Region and tissue differences of metabolites in normally aged brain using multislice 1H magnetic resonance spectroscopic imaging. Magn Reson Med
45, 899–907., , , et al.
2003. The amygdala and Alzheimer's disease: Positron emission tomographic study of the cholinergic system. Ann N Y Acad Sci
985, 411–9., , , et al.
1995. Probable Alzheimer disease: Diagnosis with proton MR spectroscopy. Radiology
195, 65–72., , , et al.
2009. Regional myo-inositol concentration in mild cognitive impairment using 1H magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord
23, 57–62., , , and .
1991. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience
45, 37–45., and .
1996. Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology
47, 696–704., , , et al.
2007. Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment. Neurology
69, 1012–7., , , et al.
1993. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci
13, 981–9., , and .
1993. Deficits in iodine-labelled 3-quinuclidinyl benzilate binding in relation to cerebral blood flow in patients with Alzheimer's disease. Eur J Nucl Med
20, 379–86., , , et al.
2006. Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-inositol using magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord
20, 77–85., , , et al.